Pharmacovigilance: Scope for a dermatologist

Indian Journal of Dermatology

Volumn 56, Issue 5, 2011, Pages 490-493

  Prakash, Bhanu ^a   Singh, Gurcharan ^b  

^a VYDEHI INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE   (India)

^b SRI DEVARAJ URS MEDICAL COLLEGE   (India)

Author keywords

Adverse drug reactions; drugs; pharmacovigilance

Indexed keywords

BENOXAPROFEN; BROMFENAC; ENCAINIDE; FLOSEQUINAN; HERBACEOUS AGENT; MIBEFRADIL; TEMAFLOXACIN; TERFENADINE; THALIDOMIDE; VACCINE;

ADVERSE DRUG REACTION; ADVERSE OUTCOME; ARTICLE; BLOOD; CLINICAL PRACTICE; CONGENITAL MALFORMATION; DERMATOLOGIST; DEVICE; DRUG APPROVAL; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HERBAL MEDICINE; HOSPITAL; HUMAN; INTERNET; LIVER NECROSIS; LIVER TOXICITY; MEDICAL SPECIALIST; MORTALITY; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SWEDEN; TRADITIONAL MEDICINE; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 81255141126     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.87121     Document Type: Article

References (15)

1. Handbook of resolutions and decisions of the World Health Assembly and Executive Board, Vol 11948-1972. Clinical and pharmacological evaluation of drugs. Geneva: World Health Organization; 1973. p. WHA16.36.
2. Available from: Available http://www.hsa.gov.sg/publish/hsaportal/en/ health-products-regulation/safety-informati. [cited in 2010].
3. Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995;39:223-6.
4. Strom BL. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley; 1994.
5. Meyboom RH, Egberts AC, Gribnau FW, Hekster YA. Pharmacovigilance in perspective. Drug Safety 1999;21:429-47. (Pubitemid 30021100)
6. Fraechia GN, Theofilatou M, editors. Legal aspects of medical devices: Study on regulatory mechanisms for safety control. Health Services Research. Amsterdam, Netherlands: IOS Press; 1993. p. 358-61.
7. Mehta U, Milstien JB, Duclos P, Folb PI. Developing a national system for dealing with adverse events following immunization. Bull World Health Organ 2000;789:170-7. (Pubitemid 30151601)
8. Craven BM, Stewart GT, Khan M. Chan TYK. Monitoring the safety of herbal medicines. Drug Safety 1997;179:209-15. (Pubitemid 27466511)
9. Effective communications in Pharmacovigilance. The Erice Report. International Conference on Developing Effective Communications in pharmacovigilance, Erice, Sicily, 24-27 September 1997, at which a policy statement was drawn up known as the Erice Declaration.
10. The importance of pharmacovigilance, safety monitoring of medicinal products. World Health Organ 2002;3:9-14.
11. WHO/EDM/QSM/2002.2; Safety of Medicines A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Geneva: World Health Organization 2002.
12. Lazarou , Pomeranz BH, Corey PN. Incidence of ADR in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1000-5.
13. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998;45:301-8. (Pubitemid 28081927)
14. White T, Arakelian A, Rho JP. Counting the cost of drug-related adverse events. Pharmacoeconomics 1999;15:445-58. (Pubitemid 29210948)
15. Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol 2001;56:935-41. (Pubitemid 33788573)